Antiminor Histocompatibility Complex (MiHA) T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Antiminor Histocompatibility Complex (MiHA) T Cells, covering 2017-12-06 to 2017-12-06. Get the full timeline:
Most recent: Clinical Trial Update: Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) [Phase 1, Phase 2]